About Dementia and Movement Disorder Treatment
Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia. Dementia can be classified into different types, based on the parts of brain affected. Among these types, Alzheimer’s disease is the most common type of dementia.
Technavio’s analysts forecast the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global dementia and movement disorder treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Dementia and Movement Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• Eisai
• Novartis
• Teva Pharmaceutical Industries
Other prominent vendors
• Amgen
• Pfizer
• UCB
• H. Lundbeck
• F. Hoffmann-La Roche
• Eli Lilly
Market driver
• Need for disease modifying drugs (DMDs)
• For a full, detailed list, view our report
Market challenge
• Social stigma associated with dementia
• For a full, detailed list, view our report
Market trend
• Emergence of biomarkers
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table Of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Dementia: An overview
• Dementia
• Epidemiology of disease
• Types of dementia
• Medical interventions to treat dementia
• Parkinson’s disease and dementia
PART 06: Movement disorder: An overview
• Movement disorders
• Cause of movement disorders
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Pipeline
PART 09: Segmentation by drug class
• Global DAMD treatment market by MAO inhibitors
• Global DAMD treatment market by AChE inhibitors
• Global DAMD treatment market by glutamate inhibitors
• Global DAMD treatment market by others
PART 10: Geographical segmentation
• DAMD treatment market in Americas
• DAMD treatment market in EMEA
• DAMD treatment market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
• Market drivers
• Market challenges
PART 13: Market trends
• Emergence of biomarkers
• Growth of gene therapy to reverse cognitive decline associated with Alzheimer’s disease
• Advances in biomedical science
PART 14: Vendor landscape
• Competitive scenario
PART 15: Key vendor analysis
• Allergan
• Eisai
• Novartis
• Teva Pharmaceutical Industries
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Functions of brain affected by dementia
Exhibit 02: Types of Alzheimer’s disease
Exhibit 03: Cognitive impairment in dementia
Exhibit 04: Types of dementia
Exhibit 05: Types of dementia by prevalence rate 2006
Exhibit 06: Vendor initiative in DAMD treatment market
Exhibit 07: Types of movement disorders
Exhibit 08: Insufficient movement disorders
Exhibit 09: Excessive movement disorders
Exhibit 10: Cause of movement disorder
Exhibit 11: Market segmentation by drug class 2016
Exhibit 12: Market snapshot: Global DAMD treatment market
Exhibit 13: Global DAMD treatment market 2016-2021 ($ millions)
Exhibit 14: Opportunity analysis of global DAMD treatment market
Exhibit 15: Five forces analysis
Exhibit 16: Pipeline landscape based on number of molecules 2016
Exhibit 17: Alzheimer’s disease: Key clinical trials
Exhibit 18: Huntington’s disease: Key clinical trials
Exhibit 19: Parkinson’s disease: Key clinical trials
Exhibit 20: Global DAMD treatment market by drug class
Exhibit 21: Global DAMD treatment market by drug-class 2016
Exhibit 22: Global DAMD treatment market by MAO inhibitors 2016-2021 ($ millions)
Exhibit 23: Global DAMD treatment market by AChE inhibitors 2016-2021 ($ millions)
Exhibit 24: Global DAMD treatment market by glutamate inhibitors 2016-2021 ($ millions)
Exhibit 25: Global DAMD treatment market by others 2016-2021 ($ millions)
Exhibit 26: Global DAMD treatment market by geography 2016 and 2021
Exhibit 27: Global DAMD treatment market by geography 2016-2021 ($ millions)
Exhibit 28: Global DAMD treatment market by geography 2016-2021
Exhibit 29: DAMD treatment market scenario in different regions
Exhibit 30: Market scenario in Americas
Exhibit 31: DAMD treatment market in Americas 2016-2021 ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: DAMD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: DAMD treatment market in APAC 2016-2021 ($ millions)
Exhibit 36: Prevalence rate of dementia 2006
Exhibit 37: Geriatric population analysis by geography in 2000 and estimates for 2030
Exhibit 38: Death rate per 100,000 in US population due to Alzheimer's disease 2010-2014
Exhibit 39: Revenue erosion of Aricept after loss of exclusivity
Exhibit 40: Competitive structure analysis of global DAMD treatment market 2016
Exhibit 41: Allergan: Key highlights
Exhibit 42: Allergan: Strength assessment
Exhibit 43: Allergan: Strategy assessment
Exhibit 44: Allergan: Opportunity assessment
Exhibit 45: Eisai: Key highlights
Exhibit 46: Eisai: Strength assessment
Exhibit 47: Eisai: Strategy assessment
Exhibit 48: Eisai: Opportunity assessment
Exhibit 49: Novartis: Key highlights
Exhibit 50: Novartis: Strength assessment
Exhibit 51: Novartis: Strategy assessment
Exhibit 52: Novartis: Opportunity assessment
Exhibit 53: Teva Pharmaceutical Industries: Pipeline molecules for treatment of neurodegenerative disorders
Exhibit 54: Teva Pharmaceutical Industries: Key highlights
Exhibit 55: Teva Pharmaceutical Industries: Strength assessment
Exhibit 56: Teva Pharmaceutical Industries: Strategy assessment
Exhibit 57: Teva Pharmaceutical Industries: Opportunity assessment
